Neal Shore
MD FACS
Medical Director
👥Biography 个人简介
Neal Shore has been a central investigator in clinical trials defining AR inhibitor therapy for non-metastatic and metastatic castration-resistant prostate cancer. He led the ARAMIS trial establishing darolutamide for nmCRPC and contributed to apalutamide studies. His research also characterized relugolix as an oral GnRH antagonist with cardiovascular advantages in prostate cancer. He has published extensively on hormonal therapy sequencing and resistance patterns in advanced prostate cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Neal Shore 的研究动态
Follow Neal Shore's research updates
留下邮箱，当我们发布与 Neal Shore（Carolina Urologic Research Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment